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Abstract
Background: Obstructive sleep apnea (OSA) is a serious, common, and underdiagnosed disorder that challenges health care resources.
While polysomnography (PSG) represents the standard diagnostic test for OSA, portable devices provide an alternative diagnostic tool when
issues of cost, time, geographic availability, or other constraints pose impediments to in-lab testing. This study compares the NovaSom
QSGe, a new sleep apnea home diagnostic system, to PSG both in the laboratory and in the home.
Methods: Fifty-one consecutive adults referred to the sleep lab for suspicion of OSA underwent one night of in-lab, simultaneous
recording of PSG and NovaSom QSG in addition to using the NovaSom QSG at home for three nights. Two separate comparisons were made
using the apnea–hypopnea index (AHI): in-lab PSG to in-lab NovaSom QSG and in-lab PSG to home NovaSom QSG.
Results: Using a clinical cut-off of AHI ¼ 15, the sensitivity and specificity of the in-lab NovaSom QSG vs. PSG were 95% and 91%,
respectively. For home NovaSom QSG vs. in-lab PSG, the sensitivity was 91% and specificity was 83%. The intra-class correlation
coefficient for the agreement between three separate nights of NovaSom QSG home data was 0.88.
Conclusions: In a patient population suspected of having OSA, the NovaSom QSG demonstrated acceptable sensitivity and specificity
both in the lab and self-administered in the home, when compared to PSG.
q 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Obstructive sleep apnea (OSA) is a common disorder
with significant morbidity and potential mortality occurring
in 2–4% of middle-aged adults [1]. Patients with untreated
OSA have a six- to 15-fold increased risk of motor vehicle
accidents [2]. OSA is associated with a reduced quality of
life [3], and is a contributor to hypertension [4–6] and
cardiovascular events [7,8].
Diagnosis and treatment of OSA can result in significant
short-term and lifetime cost savings [9]. One study found
that in the 10 years prior to diagnosis, OSA patients used
approximately twice as many health care services as non-
OSA patients [10]. Another group reported that in the year
prior to diagnosis, medical costs were twice as much for
untreated sleep apnea patients compared to age and sex
matched controls [11].
Despite the clear advantages of diagnosis and treatment
of OSA, certain potential limitations of in-lab polysomno-
graphy (PSG), the most commonly used diagnostic sleep
procedure, may at times impede the diagnostic process.
Some of these potential limitations include: the high cost of
this technician-dependent procedure, patient acceptance of
in-lab testing [12], potential for lengthy waiting periods,
limited access in geographically remote regions, significant
inter-scorer variability [13,14], night-to-night variability in
the apnea–hypopnea index (AHI) [15], and the tendency for
predominantly supine PSGs to overestimate AHI due to the
effect of position on breathing [16]. In addition, in many
regions there are not enough sleep labs to address the
demand using PSG. It is estimated that 1.17 million PSGs
are performed each year in the US [17]. Given the
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prevalence of OSA, the current in-lab capacity cannot meet
the need for diagnosis.
The significant increase in public and professional
awareness of the increased costs, quality of life issues and
dangers of untreated OSA has driven the need to find cost
effective, clinically validated tests to supplement the current
approach to diagnosis. One frequently considered strategy is
to refer patients with a high pre-test probability of having
OSA (e.g. regular loud snoring with witnessed apnea and
high Epworth Sleepiness Score) for in-home evaluation.
There are many publications regarding ambulatory
diagnostic systems and their validation to PSG. However,
most of these studies were performed only in a lab setting
[18–21], which is a controlled environment compared to the
home, where these devices are usually used. Most of the
current devices require the patient to be hooked up in the lab
or require technical assistance in the home in order to
perform the study [20,22]. Even with technical assistance,
the data loss due to poor signal quality or signal loss was
higher than if these studies had been performed in a lab
setting [23]. We recently became aware of a new device
specifically designed for self-administered home use, the
NovaSom QSG, which we evaluated for reliability and
validity in this study.
2. Materials and methods
Fifty-one consecutive adults referred to the sleep lab by a
large pool of community physicians due to a clinical
suspicion of OSA, based on symptoms including snoring,
witnessed apnea and excessive daytime sleepiness, and
scheduled for overnight in-lab PSG, signed informed
consent to participate in the study. See Table 1 for subject
characteristics and frequency of symptoms. All forms and
procedures were approved by the Sequoia Hospital
Institutional Review Board.
Patients performed a home NovaSom QSG study either
before or after their in-lab study. All recordings performed
in the sleep lab were simultaneous recordings of in-lab PSG
and NovaSom QSG. Patients received a NovaSom QSG
system from the sleep lab and were instructed to use the
system at home for three nights but received no instructions
on how to use the NovaSom QSG. Instructions for Use, a
Quick Guide and an instructional video were provided with
the NovaSom QSG system in addition to a 24 h help line.
The NovaSom QSG, manufactured by Sleep Solutions
Incorporated, is a five-channel home diagnostic system. The
NovaSom QSG measures nasal and oral airflow (using
sound), oxygen saturation, heart rate, respiration effort and
snoring sound intensity. The NovaSom QSG consists of a
bedside unit, a patient module (worn on the patient’s wrist)
and three body sensors: airflow, finger oximeter and
respiration effort. It is self-administered and used unat-
tended in the home to record three nights of data. The
system uses voice alerts to wake the patient if any of the
sensors become dislodged during the night. The NovaSom
QSG does not differentiate between wake and sleep, so the
AHI measurement is based on total recording time as
opposed to total sleep time. All subjects had standard PSG
[24] processed through analog amplifiers and recorded by
computer. The NovaSom QSG airflow respiration signal
was wired into an empty channel on the polysomnogram
montage for start time calibration. The technologist was
blinded to the NovaSom QSG signal both during recording
and scoring of the data.
Two separate sets of comparisons were made between in-
lab PSG and the NovaSom QSG. First, simultaneous
recordings of in-lab PSG and NovaSom QSG were
compared using AHI with a clinical cut-off of 15 in order
to establish the validity of NovaSom QSG. This was
accomplished by estimating the kappa coefficient to
quantify the beyond-chance agreement of the measurement
methods and by estimating the sensitivity, specificity, and
positive and negative predictive values of NovaSom QSG
using the PSG as a ‘gold standard’. The value 15 was chosen
since it is commonly used as a cut-off value for treatment
[23,25]. A second set of comparisons was made between in-
lab PSG and home NovaSom QSG. For each subject,
separate home recordings were obtained for three nights
within seven days of the lab test. A clinical cut-off of
AHI ¼ 15 was used to compare in-lab PSG-determined AHI
to each subject’s average AHI across all nights of home
testing.
Patients with AHI values of 15 or more are classified as
positive and patients with values less than 15 are classified
as negative. The kappa coefficient compares the number of
subjects positive or negative by both PSG and NovaSom
QSG to the number expected if the measurement methods
were independent of each other. If there is complete
agreement, then kappa ¼ 1. If the observed agreement is
greater than chance, then kappa is .0.
The test–retest reliability of the NovaSom QSG home
data was estimated using the intra-class correlation
coefficient (ICC). The ICC is a widely used measure of
inter-subject reliability for quantitative data.
Table 1
Subject characteristics (n ¼ 51)
Gender (M/F) 38/13
Age (years)
Mean ^ SE 52 ^ 2.1
Range 30–83
BMI
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Some of the in-lab NovaSom QSG/PSG recordings were
interrupted due to a split night protocol [26]. Each subject
agreed to use NovaSom QSG at home for three nights,
although ten subjects used it for less than three nights (two
nights by seven subjects, one night by three subjects). To
minimize order bias, half the NovaSom QSG home
recordings were performed before the in-lab recordings
and half were performed after the in-lab recordings
according to the order of referral to the Sleep Disorders
Center. The first half of the subjects referred for sleep study
used NovaSom QSG at home before their lab test and the
second half used NovaSom QSG at home after their lab test.
PSG included two channels of electroencephalogram
(EEG), electrooculogram (EOG), submentalis electromyo-
gram (EMG), electrocardiography, anterior tibialis EMG,
diaphragmatic EMG, microphone (snoring sounds), end
tidal CO2, nasal–oral airflow (thermocouple), abdominal
and thoracic respiration using piezo sensors, and oximetry
(Novametrix), all processed through a Grass polygraph and
recorded by a Sandman Diagnostics System.
Each polysomnogram was staged for sleep according to
the Rechtschaffen and Kales criteria [27] by a trained,
blinded technologist. Respiratory events from the poly-
somnogram recording were manually scored by the
technologist (RPSGT). The NovaSom QSG scoring of
events is automated. For both systems, an apnea was defined
as cessation of airflow for 10 s or longer and hypopnea was
defined as $50% reduction in airflow for 10 s or longer
accompanied by a $2% decrease in oxygen hemoglobin
saturation.
PSG traditionally divides the sum of hypopneas and
apneas by total hours of sleep to produce the AHI. Since
total-hours-of-recording is the denominator used by Nova-
Som QSG, we compared NovaSom QSG lab and NovaSom
QSG home AHI, both calculated with total recording time,
to PSG AHI calculated with total sleep time.
The NovaSom QSG system utilizes patented audio
digital-signal processing (DSP) technology to sense,
analyze, and convert the patient’s respiratory sounds to
airflow. The airflow sensor, which is worn on the patient’s
upper lip, houses two microphones. One microphone
captures the snoring sounds and ambient noise while the
other microphone captures the respiration sounds. These
two signals are processed by the adaptive noise canceling
filters in the DSP to subtract the snoring and ambient noise
from the respiration. The result is a pure respiration signal
that has a fast response time and a linear correlation with
measured airflow. The NovaSom QSG utilizes proprietary
algorithms for automated scoring and the generation of a
diagnostic report.
The NovaSom QSG effort sensor is thin Tygone tubing
placed around the chest and is connected to a pressure
transducer in the patient module. The finger sensor used by
the NovaSom QSG is a Nonin Adult Flexi-form 7000A. The
NovaSom QSG testing was unattended and self-adminis-
tered by the subject in the home.
3. Results
Because no differences were present between subjects
first using the NovaSom QSG at home vs. those first having
in-lab testing, the data were pooled for analyses.
Of the 51 subjects, 45 completed in-lab PSG plus home
NovaSom QSG. Six of the 51 subjects had no home data:
three subjects returned their home systems unused and three
subjects’ NovaSom QSG data were lost due to a faulty
memory chip. Forty-four of the 51 subjects had both PSG
and in-lab NovaSom QSG data; seven subjects were missing
NovaSom QSG in-lab data: three due to a technician
procedure error and four subjects’ data were lost due to an
error made when the NovaSom QSG data was being
uploaded. Forty of the 44 in-lab recordings were split night
studies.
The demographic data for all subjects are summarized in
Table 1. The average laboratory recording length was 239
min (range 62–409 min; SD 118). The average home
recording length was 379 min (range 58–467 min; SD 123).
3.1. NovaSom QSG lab vs. PSG: AHI 15 as threshold
We used the kappa coefficient to estimate the beyond-
chance agreement between NovaSom QSG lab and PSG
AHI results. The value of kappa was 0.864 ^ 0.076 SE
Table 2
Sensitivity, specificity and predictive values of NovaSom QSG
AHI cut-off ¼ 15
In-lab Home
Sensitivity (%) 95 91
Specificity (%) 91 83
Positive predictive value (%) 91 83
Negative predictive value (%) 96 91
Fig. 1. Bland Altman plot for PSG vs. in-lab NovaSom QSG. Reference
lines are ^1 SD (dotted) and ^2 SD (solid).
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which represents excellent agreement beyond chance [28].
This measure of agreement directly compares the two
methods without assuming the polysomnogram values
should be used as a ‘gold standard’ of comparison. With
the in-lab results, among 44 subjects, 20 were positive and
21 were negative by both measuring modalities. Thus, the
observed agreement equals 41=44 ¼ 0:932. However, by
chance alone this proportion is expected to equal
22=44 ¼ 0:50. The kappa coefficient is defined as the
difference of these proportions divided by the maximum
possible beyond-chance proportion, i.e. for the example
kappa ¼ ð0:932 2 0:50Þ=ð1:0 2 0:50Þ ¼ 0:864.
Using PSG as the gold standard, the sensitivity and
specificity of NovaSom QSG lab was 95 ^ 5% and
91 ^ 6%, respectively, the negative predictive value was
96 ^ 4% and the positive predictive value was 91 ^ 6%
(see Table 2).
Fig. 1 shows a Bland Altman plot of the difference in
AHI against the mean AHI for PSG vs. in-lab NovaSom
QSG.
3.2. NovaSom QSG home vs. PSG: AHI 15 as threshold
The kappa coefficient between each subject’s average
NovaSom QSG home and lab PSG AHI results was
0.734 ^ 0.101 SE. Referring to PSG as the gold standard,
the sensitivity and specificity of NovaSom QSG home was
91 ^ 6% and 83 ^ 8%. The negative predictive value was
91 ^ 6% and the positive predictive value was 83 ^ 8%
(see Table 2). As expected, these results are somewhat
lower than for the in-lab comparisons, since the in-lab night
and home nights were not the same.
Fig. 2 shows a Bland Altman plot of the difference in
AHI against the mean AHI for PSG vs. home NovaSom
QSG.
3.3. NovaSom QSG lab vs. NovaSom QSG home
Sensitivities and specificities were compared between
NovaSom QSG lab and average NovaSom QSG home using
AHI with a clinical cut-off of 15 and PSG as the gold
standard. Eighteen subjects had both in-lab and home values
when the PSG was positive. The sensitivity of NovaSom
QSG lab was 94 ^ 5% SE and NovaSom QSG home was
89 ^ 7% SE. The difference in the sensitivities equals
5.5 ^ 5.4% SE with a P value of 0.31. Twenty subjects had
both in-lab and home values when the PSG was negative.
The specificity of NovaSom QSG lab was 90.0 ^ 6.7% and
NovaSom QSG home was 80.0 ^ 8.9%. The difference in
the specificities equals 10.0 ^ 6.7% with a P value of 0.14.
The agreement of the NovaSom QSG home AHIs was
determined using an ICC. The ICC for the night-to-night
home data was 0.88 ^ 0.034, representing excellent night-
to-night reliability.
Fig. 3 shows a Bland Altman plot of the difference in
AHI against the mean AHI for in-lab NovaSom QSG vs.
home NovaSom QSG.
3.4. Patient use at home without technician assistance
Ninety-four percent of the subjects (45/48) successfully
used the NovaSom QSG system at home without technician
assistance. Three subjects returned the device unused. The
three subjects whose data were lost due to a faulty memory
chip could not be included in the analysis because it could
not be determined that the systems were properly used.
There were no subjects who were unable to use the
NovaSom QSG and there were no invalid home studies
due to misapplied sensors. A 24 h help line was not utilized
by any of the patients.
4. Discussion
This study attempts to compare the NovaSom QSG
diagnostic system in the home and lab with conventional in-
lab PSG. The study also examines the reliability of the
Fig. 2. Bland Altman plot for PSG vs. home NovaSom QSG. Reference
lines are ^1 SD (dotted) and ^2 SD (solid).
Fig. 3. Bland Altman plot for NovaSom QSG in-lab vs. NovaSom QSG
home. Reference lines are ^1 SD (dotted) and ^2 SD (solid).
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NovaSom QSG by assessing the agreement among findings
obtained on separate home study nights.
The data showed very high concordance between the in-
lab NovaSom QSG and PSG when performed simul-
taneously in the lab. Sensitivity and negative predictive
values of 95% and 96%, respectively, indicate that the
NovaSom QSG is capable of accurately determining
negative cases, i.e. ruling out sleep apnea over a wide
range of values. The home NovaSom QSG sensitivity and
negative predictive values were 91%. These home values
are slightly lower than the in-lab values, and may be
attributable to night-to-night variance in sleep patterns and
AHI. The negative prediction capability is important when
home study is used as a diagnostic study rather than a
screening device.
The simultaneous in-lab NovaSom QSG/PSG specificity
and positive predictive values were 91%, which is clinically
acceptable. There were four false positives in the home
NovaSom QSG vs. PSG which reduced the specificity and
positive predictive values to 83%. If the cut-off value were
18 rather than 15, all four home NovaSom QSG false
positive cases would have been eliminated, yielding a
specificity and positive predictive value of 100%. This
observation points out the arbitrary nature of cut-offs,
however necessary to estimate performance of methods.
While these four cases are statistically categorized as false
positives, the clinical decision whether or not to treat is
based on many factors in addition to the AHI and the
difference between an AHI of 15 and 18 is clinically
insignificant.
Two subjects had a false negative (below 15) AHI result
in the home. In both cases, the majority of respiratory events
scored by the technician on PSG were hypopneas as
opposed to apneas (one subject had all hypopneas). The
discrepancy in both cases could be due to the difference in
signals and scoring methodology or night-to-night
variability.
There has been much debate about how to use home
devices. Due to the relatively high specificity of the
NovaSom QSG a three night home sleep study would be
useful if a high probability of sleep apnea is suspected. The
usual clinical clues include snoring, witnessed apneas, and
concomitant corroborating signs and symptoms. In this case
the diagnosis is mainly clinical and the in-home test
corroborates the diagnosis and gives an indication of the
severity.
The NovaSom QSG also demonstrated a high sensitivity
in our patient population where OSA was suspected. Our
patient population did not allow us to test whether NovaSom
QSG sensitivity would remain high in subjects with a low
probability of OSA. Future studies need to include a wider
range of disease severity to test this hypothesis.
Home sleep studies are also convenient means of
assessing treatment, i.e. post-surgical, post-weight
reduction, positional therapy, dental appliances, etc.
The NovaSom QSG differs from currently available
home systems in several ways. The system is sent directly to
the patient’s home, uses voice alerts to guide the patient
during application of the sensors and during recording, and
provides multiple nights of data. This gives the physician
information about night-to-night variability [15,29] as well
as access to additional information not obtainable with a
one-night study, e.g. by altering night-to-night variables
such as alcohol intake or sleeping position. Finally, the
automated scoring eliminates the problem of inter-scorer
variability [14] and regional differences in AHI criteria.
Two drawbacks of the NovaSom QSG compared to PSG
are evident. The NovaSom QSG does not have a body
position sensor, therefore position-related apnea cannot be
determined. However, many patients with position-related
apnea are ultimately treated with CPAP, as the long-term
effectiveness of position-modification training is unknown.
The NovaSom QSG does not record EEG, therefore sleep
onset is not definitely known and sleep staging is not
possible. Nonetheless, despite the lack of EEG, the overall
AHI comparisons were very good.
As has been pointed out in previous publications, there
are some inherent flaws in comparing devices across nights
and in different environments [30]. Night-to-night varia-
bility can occur in both sleep patterns and AHI. Therefore, it
is expected that the agreement between the two devices on
different nights would be lower than the agreement between
the two devices on the same night in the same environment.
There are some limitations of PSG (the current ‘gold
standard’): high overhead costs due to the need for
dedicated rooms and full-time technologists, the require-
ment of night-shift workers, variable scoring criteria from
sleep lab to sleep lab, inter-scorer variability, and the
unfamiliar lab environment which alters the patient’s sleep
architecture. While there seems to be a transition occurring
from the use of thermistors to nasal cannula/pressure
transducers, no true gold standard for respiratory airflow
currently exists.
In conclusion, the NovaSom QSG is a sensitive and
reliable home diagnostic system that could be used in the
diagnosis of OSA.
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